Difference between revisions of "Team:ETH Zurich"
| Line 123: | Line 123: | ||
</div> | </div> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="CH" width="500px" align="left"> | ||
| + | <!-- | ||
| + | CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors. We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites. | ||
| + | Project description | ||
| + | |||
| + | --> | ||
Revision as of 13:46, 7 October 2017
Cancer kills over 8 million people every year. That's the entire population of Switzerland!
We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.
Learn more
We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.
Learn more
